Free Trial
NASDAQ:UBX

Unity Biotechnology Q4 2023 Earnings Report

Unity Biotechnology logo
$0.79 -0.02 (-2.36%)
As of 09:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Unity Biotechnology EPS Results

Actual EPS
-$0.53
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Unity Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unity Biotechnology Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, April 15, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Unity Biotechnology's Q2 2025 earnings is scheduled for Tuesday, August 5, 2025

Unity Biotechnology Earnings Headlines

Unity Biotechnology (NASDAQ:UBX) Cut to "Neutral" at Mizuho
Washington Is Broke—and Eyeing Your Savings Next
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
Unity Biotechnology (UBX) to Release Earnings on Tuesday
See More Unity Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unity Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unity Biotechnology and other key companies, straight to your email.

About Unity Biotechnology

Unity Biotechnology (NASDAQ:UBX), a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

View Unity Biotechnology Profile

More Earnings Resources from MarketBeat